Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-1601015
  • Global Ophthalmology Drug & Devices Market insights, Opportunities, Analysis, Market Shares and Forecast 2017 – 2023

  • Publish: January 2016 | Report Code: HPH-1601015

* For discount/customization and buying a particular chapter click here or write to us at sales@occamsresearch.com

Ophthalmic drugs are the ointments which treat eye related disorders and are nonirritant. The global ophthalmic drug market is expected to grow at 6.9% by 2022. This industry is dominated by a bunch of companies having high growth potentials. In the recent years, due to the impact of generic prostaglandin analogues, the ophthalmic drugs market has been transformed.

The rising eye related disorders in the world, changing lifestyle, and rising healthcare expenditure are the major driving factors in the growth of the global ophthalmic drug market. Also, due to the growth in healthcare services, the life expectancy rate has also increased, which in turn is increasing the number of elderly or geriatric population worldwide. This elderly population is more likely to suffer from eyesight disorders like presbyopia, diabetic retinopathy, and muscular degeneration. With the upcoming sophisticated technology, people now to correct their eye related disorders are increasingly opting for ophthalmic surgeries.

The major types of ophthalmic drugs available in the global market are the prescription drugs and the Over the counter (OTC) drugs. OTC drugs are for ocular allergy and dry eyes and can be given without the need of prescription. On the basis of treatment, ophthalmic drugs are segmented as retinal drugs, Anti-glaucoma drugs, and Anti-inflammatory/ infective drugs, which are given on the basis of diagnosed condition. The anti-glaucoma drug acquires the largest market share in the global ophthalmic treatment drugs market. The ocular anesthetics are the drugs that are used by surgeons during a surgery.

The major constraints of the global ophthalmic drug market are the lack of awareness among the people related to eye disorders in the underdeveloped and developing countries, patent expiry of various blockbuster drugs, and the absence of health insurance is affecting the market adversely.

The global ophthalmic drug market is dominated by North America (US) due to increased initiatives to reduce blindness, as well as other related disorders amongst the geriatric population, followed by Europe (Germany, UK, and France), Asia Pacific and LAMEA.  Asia Pacific is expected to be one of the fastest growing markets for ophthalmic drugs in the world during the forecasted period, as the elderly population is more prone to suffer from eye related disorders due to age. Southeast Asian nations like India and China are the major consumers of the ophthalmic drugs which provide growth to the global ophthalmic drug market.

The key market players of the industry are continuously investing in research and development, for product launch with new combinations of therapies, and mergers and acquisitions.

Market leader in the ophthalmic drug market is Novartis, holding 24%of the total market share. Major players of the global ophthalmic drug market are Pfizer, Allergan, Santen, Roche, Bayer, Merck and Co., Valeant, Regeneron, and Senju.

1.            INTRODUCTION

# 1.1.     EXECUTIVE SUMMARY

# 1.2.     ESTIMATION METHODOLOGY

2.            MARKET OVERVIEW

# 2.1.     MARKET DEFINITION AND SCOPE

# 2.2.     KEY FINDINGS

# 2.3.     PARAMETRIC ANALYSIS

# 2.3.1. PREVALENCE & INCIDENCE RATE OF EYE DISORDERS

# 2.3.2. HOSPITAL AND EYE CLINIC ACROSS GEOGRAPHIES

# 2.3.3. INCREASING CATARACT SURGERIES

# 2.3.4. HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES

# 2.3.5. DISPOSABLE INCOME OF TOP EMERGING ECONOMIES

# 2.4.     KEY MARKET INSIGHTS

# 2.4.1. TOP 3 EMERGING COUNTRIES

# 2.4.2. TOP REVENUE GENERATING SEGMENTS 2014-2023 ($ MILLION)

# 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS

# 2.4.4. PIPELINE ANALYSIS

# 2.4.4.1.              SHP616: ACUTE NEUROMYELITIS OPTICA

# 2.4.4.2.              SHP622: FRIEDREICH’S ATAXIA

# 2.4.4.3.              SHP606: DRY EYE DISEASE

# 2.4.4.4.              LIFITEGRAST: DRY EYE DISEASE

# 2.4.4.5.              MIM-D3: DRY EYE DISEASE

# 2.4.4.6.              EBI-005: DRY EYE DISEASE

# 2.4.4.7.              RU-101: DRY EYE DISEASE:

# 2.4.4.8.              OTX-DP: DRY EYE DISEASE

# 2.4.5. R&D SCENARIO IN OPHTHALMOLOGY MARKET

# 2.4.5.1.              PLASMA TECHNOLOGY IN OPHTHALMOLOGY

# 2.4.5.2.              CORNIAL TOPOGRAPHY & CORNIAL ANALYSIS

# 2.4.5.3.              SCOPE OF VIRTUAL REALITY TECHNOLOGY IN EYE CARE

# 2.5.     COMPETITIVE LANDSCAPE

# 2.5.1. MARKET SHARE ANALYSIS

# 2.5.2. TOP WINNING STRATEGIES

# 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES

# 2.6.     PORTER’S FIVE FORCE MODEL

# 2.7.     VALUE CHAIN ANALYSIS

# 2.7.1. SUPPLIERS

# 2.7.2. MANUFACTURERS

# 2.7.3. DISTRIBUTORS AND RETAILERS

# 2.7.4. END USERS

# 2.8.     KEY BUYING CRITERIA

# 2.9.     STRATEGIC RECOMMENDATION

# 2.10.   STRATEGIC CONCLUSIONS

3.            MARKET DETERMINANTS

# 3.1.     MARKET DRIVERS

# 3.1.1. FDA APPROVALS GIVING RISE TO ADOPTION OF DRUGS AND DEVICES

# 3.1.2. HIGH PREVALENCE RATE OF REFRACTIVE ERRORS DRIVING THE SURGERIES IN OPHTHALMOLOGY MARKET

# 3.1.3. GLOBAL RISE IN GERIATRIC POPULATION PUSHING OPHTHALMOLOGY DRUGS MARKET

# 3.1.4. GLOBAL INCREASE IN PREVALENCE RATE OF EYE DISEASES

# 3.1.5. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE

# 3.1.6. GLOBAL INCREASE IN MINIMALLY INVASIVE SURGERIES

# 3.2.     MARKET RESTRAINT ANALYSIS

# 3.2.1. MAJOR DRUGS GOING OFF PATENT IS AFFECTING THE GROWTH OF OPHTHALMOLOGY MARKET

# 3.2.2. DRYING PIPELINES IS A CONCERN FOR MAJOR PLAYERS

# 3.3.     MARKET OPPORTUNITIES

# 3.3.1. INTRAOCULAR LENSES, PHACOEMULSIFICATION DEVICES AND INCREASING CATARACT SURGERIES TO CREATE OPPORTUNITIES IN EMERGING ECONOMIES

# 3.3.2. INCREASE IN DIABETIC RETINOPATHIES RISING THE DEMAND FOR VITREORETINAL SURGERIES

# 3.3.3. INCREASING AWARENESS

# 3.4.     MARKET CHALLENGES

# 3.4.1. RISK ASSOCIATED WITH THE OCULAR DISEASES

# 3.4.2. LACK OF AWARENESS FOR OPHTHALMOLOGY DRUG AND DEVICE

# 3.4.3. SLOW ECONOMIC GROWTH IN DEVELOPING REGIONS MAY AFFECT THE OPHTHALMOLOGY DRUG AND DEVICE MARKET

4.            SECTOR ANALYSIS

# 4.1.     PARENT MARKET

# 4.2.     SUB-SEGMENT MARKET

# 4.3.     ALTERNATIVE MARKET

5.            TOP OPHTHALMIC DRUGS BRANDS

6.            MARKET SEGMENTATION

# 6.1.     GLOBAL OPHTHALMOLOGY DEVICE MARKET

# 6.1.1. GLOBAL OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2014-2023 ($ MILLION)

# 6.1.1.1.              GLOBAL OPTICAL COHERENCE TOMOGRAPHY SCANNERS MARKET 2014-2023 ($ MILLION)

# 6.1.1.2.              GLOBAL OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS MARKET 2014-2023 ($ MILLION)

# 6.1.1.3.              GLOBAL FUNDUS CAMERA MARKET 2014-2023 ($ MILLION)

# 6.1.1.4.              GLOBAL OPHTHALMOSCOPES 2014-2023 ($ MILLION)

# 6.1.1.5.              GLOBAL RETINOSCOPE MARKET 2014-2023 ($ MILLION)

# 6.1.1.6.              GLOBAL PACHYMETER MARKET 2014-2023 ($ MILLION)

# 6.1.1.7.              GLOBAL WAVEFRONT ABERROMETERS MARKET 2014-2023 ($ MILLION)

# 6.1.1.8.              GLOBAL PERIMETERS/VISUAL FIELD ANALYZER MARKET 2014-2023 ($ MILLION)

# 6.1.1.9.              GLOBAL AUTOREFRACTORS/PHOROPTER MARKET 2014-2023 ($ MILLION)

# 6.1.1.10.           GLOBAL KERATOMETERS 2014-2022 MARKET ($ MILLION)

# 6.1.1.11.           GLOBAL SPECULAR MICROSCOPE MARKET 2014-2023 ($ MILLION)

# 6.1.1.12.           GLOBAL CORNEAL TOPOGHAPHERS MARKET 2014-2023 ($ MILLION)

# 6.1.1.13.           GLOBAL TONOMETERS MARKET 2014-2023 ($ MILLION)

# 6.1.1.14.           GLOBAL SLIT LAMPS MARKET 2014-2023 ($ MILLION)

# 6.1.1.15.           GLOBAL BIOMETERS MARKET 2014-2023 ($ MILLION)

# 6.1.1.16.           GLOBAL OTHER MARKET 2014-2023 ($ MILLION)

# 6.1.2. GLOBAL OPHTHALMOLOGY SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.1.              GLOBAL CATARACT SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.1.1.          GLOBAL INTRAOCULAR LENS MARKET 2014-2023 ($ MILLION)

# 6.1.2.1.2.          GLOBAL PHACOEMULSIFICATION DEVICES MARKET 2014-2023 ($ MILLION)

# 6.1.2.1.3.          GLOBAL OPHTHALMIC VISCOELASTIC DEVICES MARKET 2014-2023 ($ MILLION)

# 6.1.2.2.              GLOBAL GLAUCOMA SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.2.1.          GLOBAL STENTS AND IMPLANT MARKET 2014-2023 ($ MILLION)

# 6.1.2.2.2.          GLOBAL GLAUCOMA DRAINAGE DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.2.3.          GLOBAL GLAUCOMA SYSTEM MARKET 2014-2023 ($ MILLION)

# 6.1.2.2.4.          GLOBAL GLAUCOMA LASER MARKET 2014-2023 ($ MILLION)

# 6.1.2.3.              GLOBAL REFRACTIVE SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.3.1.          GLOBAL EXCIMER LASER MARKET 2014-2023 ($ MILLION)

# 6.1.2.3.2.          GLOBAL EMCROKERATOME MARKET 2014-2023 ($ MILLION)

# 6.1.2.3.3.          GLOBAL FEMTOSECOND LASER MARKET 2014-2023 ($ MILLION)

# 6.1.2.3.4.          GLOBAL YAG LASER MARKET 2014-2023 ($ MILLION)

# 6.1.2.4.              GLOBAL VITREORETINAL SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.4.1.          GLOBAL PHOTOCOAGULATION LASER MARKET 2014-2023 ($ MILLION)

# 6.1.2.4.2.          GLOBAL ILLUMINATION DEVICE MARKET 2014-2023 ($ MILLION)

# 6.1.2.4.3.          GLOBAL VITRECTOMY MACHINE MARKET 2014-2023 ($ MILLION)

# 6.2.     GLOBAL VISION CARE MARKET 2014-2023 ($ MILLION)

# 6.2.1. GLOBAL CONTACT LENS MARKET 2014-2023 ($ MILLION)

# 6.2.2. GLOBAL SPECTACLES MARKET 2014-2023 ($ MILLION)

# 6.2.3. GLOBAL EYE EXAMS MARKET 2014-2023 ($ MILLION)

# 6.3.     GLOBAL OPHTHALMOLOGY DRUG MARKET 2014-2023 ($ MILLION)

# 6.3.1. GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2014-2023 ($ MILLION)

# 6.3.1.1.              GLOBAL PRESCRIPTION BASED OPHTHALMIC DRUGS MARKET 2014-2023 ($ MILLION)

# 6.3.1.2.              GLOBAL OTC (OVER THE COUNTER DRUGS) OPHTHALMIC DRUGS MARKET 2014-2023 ($ MILLION)

# 6.3.2. GLOBAL DRUG DELIVERY TYPES 2014-2023 ($ MILLION)

# 6.3.2.1.              GLOBAL EYE DROPS MARKET 2014-2023 ($ MILLION)

# 6.3.2.2.              GLOBAL CAPSULES & TABLET MARKET 2014-2023 ($ MILLION)

# 6.3.2.3.              GLOBAL EYE OINTMENT MARKET 2014-2023 ($ MILLION)

# 6.3.2.4.              GLOBAL EYE GEL MARKET 2014-2023 ($ MILLION)

# 6.3.2.5.              GLOBAL EYE SOLUTION MARKET 2014-2023 ($ MILLION)

# 6.4.     GLOBAL OPHTHALMOLOGY DRUG MARKET BY TYPE OF DISEASE 2014-2022($ MILLION)

# 6.4.1. GLOBAL GLAUCOMA DRUG MARKET 2014-2022($ MILLION)

# 6.4.1.1.              XALATAN (LATANOPROST)/XALACOM (LATANOPROST AND TIMOLOL COMBINATION) (XALABRANDS)

# 6.4.1.2.              LUMIGAN FRANCHISE [LUMIGAN (BIMATOPROST) + GANFORT (BIMATOPROST AND TIMOLOL COMBINATION)]

# 6.4.1.3.              TAPROS/TAFLOTAN (TAFLUPROST)

# 6.4.1.4.              SAFLUTAN/ZIOPTAN (TAFLUPROST)

# 6.4.1.5.              ALPHAGAN (BRIMONIDINE)/COMBIGAN (BRIMONIDINE AND TIMOLOL COMBINATION)

# 6.4.1.6.              COSOPT (DORZOLAMIDE AND TIMOLOL COMBINATION)/ TRUSOPT (DORZOLAMIDE)

# 6.4.1.7.              AZARGA (BRINZOLAMIDE AND TIMOLOL COMBINATION)

# 6.4.1.8.              AZOPT (BRINZOLAMIDE)

# 6.4.2. GLOBAL RETINAL DISORDER MARKET 2014-2023 ($ MILLION)

# 6.4.2.1.              LUCENTIS (RANIBIZUMAB)

# 6.4.2.2.              VISUDYNE (VERTEPORFIN)

# 6.4.2.3.              AVASTIN (BEVACIZUMAB)

# 6.4.2.4.              EYLEA (AFLIBERCEPT)

# 6.4.3. GLOBAL DRY EYE DRUG MARKET 2014-2022($ MILLION)

# 6.4.3.1.              RESTASIS (CYCLOSPORINE)

# 6.4.3.2.              HYALEIN (SODIUM HYALURONATE)

# 6.4.3.3.              DIQUAS (DIQUAFOSOL SODIUM)

# 6.4.4. GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2014-2022($ MILLION)

# 6.4.4.1.              PATANOL/PATADAY/OPATANOL (OLOPATADINE)

# 6.4.4.2.              BEPREVE (BEPOTASTINE BESILATE)

# 6.4.4.3.              TOBRADEX (TOBRAMYCIN & DEXAMETHASONE COMBINATION)

# 6.4.4.4.              XIBROM/BROMDAY (BROMFENAC)

# 6.4.4.5.              VIGAMOX

# 6.4.4.6.              AZASITE (AZITHROMYCIN)

# 6.5.     GLOBAL OPHTHALMOLOGY DRUG AND DEVICE MARKET BY THERAPEUTICS 2014-2023 ($ MILLION)

# 6.5.1. GLOBAL DIABETIC MACULAR EDEMA MARKET 2014-2023 ($ MILLION)

# 6.5.2. GLOBAL EYE CANCER MARKET 2014-2023 ($ MILLION)

# 6.5.3. GLOBAL DIABETIC RETINOPATHY MARKET 2014-2023 ($ MILLION)

# 6.5.4. GLOBAL RETINAL VEIN OCCLUSION MARKET 2014-2023 ($ MILLION)

# 6.5.5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET 2014-2023 ($ MILLION)

# 6.5.6. GLOBAL CONJUNCTIVITIS MARKET 2014-2023 ($ MILLION)

# 6.5.7. GLOBAL DRY EYE MARKET 2014-2023 ($ MILLION)

# 6.5.8. GLOBAL GLAUCOMA MARKET 2014-2023 ($ MILLION)

# 6.5.9. GLOBAL KERATITIS MARKET 2014-2023 ($ MILLION)

# 6.5.9.1.              GLOBAL GEOGRAPHIC ATROPHY MARKET 2014-2023 ($ MILLION)

# 6.6.     GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2014-2023 ($ MILLION)

# 6.6.1. GLOBAL HOSPITALS MARKET 2014-2023 ($ MILLION)

# 6.6.2. GLOBAL EYE CLINICS MARKET 2014-2023 ($ MILLION)

# 6.6.3. GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET 2014-2023 ($ MILLION)

# 6.6.4. GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET 2014-2023 ($ MILLION)

7.            GEOGRAPHIC ANALYSIS

# 7.1.     NORTH AMERICA MARKET 2014-2023 ($ MILLION)

# 7.1.1. UNITED STATES (U.S.) MARKET 2014-2023 ($ MILLION)

# 7.1.2. CANADA MARKET 2014-2023 ($ MILLION)

# 7.2.     EUROPE MARKET 2014-2023 ($ MILLION)

# 7.2.1. UNITED KINGDOM (UK) MARKET 2014-2023 ($ MILLION)

# 7.2.2. FRANCE MARKET 2014-2023 ($ MILLION)

# 7.2.3. GERMANY MARKET 2014-2023 ($ MILLION)

# 7.2.4. SPAIN MARKET 2014-2023 ($ MILLION)

# 7.2.5. ITALY MARKET 2014-2023 ($ MILLION)

# 7.2.6. ROE MARKET 2014-2023 ($ MILLION)

# 7.3.     ASIA PACIFIC MARKET 2014-2023 ($ MILLION)

# 7.3.1. INDIA MARKET 2014-2023 ($ MILLION)

# 7.3.2. CHINA MARKET 2014-2023 ($ MILLION)

# 7.3.3. JAPAN MARKET 2014-2023 ($ MILLION)

# 7.3.4. KOREA MARKET 2014-2023 ($ MILLION)

# 7.3.5. AUSTRALIA MARKET 2014-2023 ($ MILLION)

# 7.3.6. ROAPAC MARKET 2014-2023 ($ MILLION)

# 7.4.     REST OF THE WORLD MARKET 2014-2023 ($ MILLION)

# 7.4.1. LATIN AMERICA MARKET 2014-2023 ($ MILLION)

# 7.4.2. MENA MARKET 2014-2023 ($ MILLION)

# 7.4.3. SOUTH AFRICA MARKET 2014-2023 ($ MILLION)

8.            COMPANY PROFILES

# 8.1.     ABBOTT LABORATORIES

# 8.1.1. COMPANY OVERVIEW

# 8.1.2. SCOT ANALYSIS

# 8.1.3. PRODUCT PORTFOLIO

# 8.1.4. STRATEGIC INITIATIVES

# 8.2.     AKORN

# 8.2.1. COMPANY OVERVIEW

# 8.2.2. SCOT ANALYSIS

# 8.2.3. PRODUCT PORTFOLIO

# 8.2.4. STRATEGIC INITIATIVES

# 8.3.     ALLERGAN INC.

# 8.3.1. COMPANY OVERVIEW

# 8.3.2. PRODUCT PORTFOLIO

# 8.3.3. STRATEGIC INITIATIVES

# 8.4.     BAYER

# 8.4.1. COMPANY OVERVIEW

# 8.4.2. PRODUCT PORTFOLIO

# 8.4.3. STRATEGIC INITIATIVES

# 8.5.     CIPLA PHARMACEUTICALS

# 8.5.1. COMPANY OVERVIEW

# 8.5.2. SCOT ANALYSIS

# 8.5.3. PRODUCT PORTFOLIO

# 8.5.4. STRATEGIC MOVES

# 8.6.     EYEGATE PHARMACEUTICALS

# 8.6.1. COMPANY OVERVIEW

# 8.6.2. PRODUCT PORTFOLIO

# 8.6.3. STRATEGIC MOVES

# 8.7.     EYEMED

# 8.7.1. COMPANY OVERVIEW

# 8.7.2. PRODUCT PORTFOLIO

# 8.7.3. STRATEGIC INITIATIVES

# 8.8.     GLAXOSMITHKLINE

# 8.8.1. COMPANY OVERVIEW

# 8.8.2. PRODUCT PORTFOLIO

# 8.8.3. STRATEGIC MOVES

# 8.9.     JOHNSON AND JOHNSON

# 8.9.1. COMPANY OVERVIEW

# 8.9.2. PRODUCT PORTFOLIO

# 8.9.3. STRATEGIC INITIATIVES

# 8.10.   LPATH

# 8.10.1.               COMPANY OVERVIEW

# 8.10.2.               PRODUCT PORTFOLIO

# 8.11.   MERCK & CO.

# 8.11.1.               COMPANY OVERVIEW:

# 8.11.2.               PRODUCT PORTFOLIO

# 8.11.3.               STRATEGIC MOVES

# 8.12.   BIOTECH VISIONCARE

# 8.12.1.               COMPANY OVERVIEW

# 8.12.2.               SCOT ANALYSIS

# 8.12.3.               PRODUCT PORTFOLIO

# 8.13.   CARL ZEISS MEDIATEK AG

# 8.13.1.               COMPANY OVERVIEW

# 8.13.2.               SCOT ANALYSIS

# 8.13.3.               PRODUCT PORTFOLIO

# 8.13.4.               STRATEGIC MOVES

# 8.14.   ELLEX

# 8.14.1.               COMPANY OVERVIEW

# 8.14.2.               SCOT ANALYSIS

# 8.14.3.               PRODUCT PORTFOLIO

# 8.15.   NIDEK CO. LTD

# 8.15.1.               COMPANY OVERVIEW

# 8.15.2.               SCOT ANALYSIS

# 8.15.3.               PRODUCT PORTFOLIO

# 8.16.   NOVARTIS AG

# 8.16.1.               COMPANY OVERVIEW

# 8.16.2.               SCOT ANALYSIS

# 8.16.3.               PRODUCT PORTFOLIO

# 8.16.4.               STRATEGIC MOVES

# 8.17.   PFIZER INC.

# 8.17.1.               COMPANY OVERVIEW

# 8.17.2.               PRODUCT PORTFOLIO

# 8.17.3.               STRATEGIC INITIATIVES

# 8.18.   REGENERON

# 8.19.   COMPANY OVERVIEW

# 8.19.1.               PRODUCT PORTFOLIO

# 8.19.2.               STRATEGIC INITIATIVES

# 8.19.3.               ROCHE HOLDING AG

# 8.19.4.               COMPANY OVERVIEW

# 8.19.5.               PRODUCT PORTFOLIO

# 8.19.6.               STRATEGIC MOVES

# 8.20.   SENJU PHARMACEUTICAL CO., LTD

# 8.20.1.               COMPANY OVERVIEW

# 8.20.2.               PRODUCT PORTFOLIO

# 8.20.3.               STRATEGIC INITIATIVES

# 8.21.   SUN PHARMACEUTICALS INDUSTRIES, LTD.

# 8.21.1.               COMPANY OVERVIEW

# 8.21.2.               PRODUCT PORTFOLIO

# 8.21.3.               STRATEGIC MOVES

# 8.22.   SANTEN PHARMACEUTICAL CO.LTD

# 8.22.1.               COMPANY OVERVIEW

# 8.22.2.               SCOT ANALYSIS

# 8.22.3.               PRODUCT PORTFOLIO

# 8.22.4.               STRATEGIC INITIATIVES

# 8.23.   STAAR SURGICAL COMPANY

# 8.23.1.               COMPANY OVERVIEW

# 8.23.2.               SCOT ANALYSIS

# 8.23.3.               PRODUCT PORTFOLIO

# 8.24.   TOPCON CORPORATION

# 8.24.1.               COMPANY OVERVIEW

# 8.24.2.               SCOT ANALYSIS

# 8.24.3.               PRODUCT PORTFOLIO

# 8.24.4.               STRATEGIC INITATIVES

# 8.25.   VALEANT

# 8.25.1.               COMPANY OVERVIEW

# 8.25.2.               SCOT ANALYSIS

# 8.25.3.               PRODUCT PORTFOLIO

# 8.25.4.               STRATEGIC INITIATIVES

# 8.26.   VISIONCARE OPHTHALMIC TECHNOLOGIES

# 8.26.1.               COMPANY OVERVIEW

# 8.26.2.               SCOT ANALYSIS

# 8.26.3.               PRODUCT PORTFOLIO

# 8.26.4.               STRATEGIC INITIATIVES

# 8.27.   ZIEMER OPHTHALMIC SYSTEMS AG

# 8.27.1.               COMPANY OVERVIEW

# 8.27.2.               SCOT ANALYSIS

# 8.27.3.               PRODUCT PORTFOLIO

# 8.27.4.               STRATEGIC INITIATIVES

# 8.28.   HAAG-STREIT GROUP

# 8.28.1.               COMPANY OVERVIEW

# 8.28.2.               PRODUCT PORTFOLIO

# 8.28.3.               SCOT ANALYSIS

# 8.28.4.               STRATEGIC INITIATIVE

# 8.29.   IRIDEX CORPORATION

# 8.29.1.               COMPANY OVERVIEW

# 8.29.2.               PRODUCT PORTFOLIO

# 8.29.3.               SCOT ANALYSIS

TABLE LIST

1              GLOBAL OPHTHALMIC DRUGS AND DEVICE MARKET BY PRODUCT 2014-2023 ($ MILLION)

2              U.S. HOSPITAL FACT SHEET, 2016

3              HEALTH EXPENDITURE PER CAPITA INCREASED FROM 2010 TO 2014 ($)

4              APPLICATION OF VIRTUAL REALITY IN EYE CARE

5              CASE STUDY OF VIRTUAL REALITY IN GLAUCOMA RESEARCH

6              TOP WINNING STRATEGIES

7              DRUGS AND DEVICES APPROVED BY FDA

8              SYMPTOMS OF SOME COMMON CAUSES OF LOSS OF VISION IN ELDERLY PATIENTS

9              EYE DRUGS GONE PATENT OFF

10           FACTS ABOUT CATARACT SURGERIES FROM DEVELOPING ECONOMIES

11           TOP OPHTHALMIC DRUGS BRANDS

12           GLOBAL OPHTHALMOLOGY DEVICE MARKET BY GEOGRAPHY 2014-2022($MILLION)

13           GLOBAL OPHTHALMOLOGY DEVICE MARKET 2014-2023 ($ MILLION)

14           GLOBAL OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET 2014-2023 ($ MILLION)

15           SCANS PERFORMED BY DOMAINS

16           GLOBAL OPTICAL COHERENCE TOMOGRAPHY SCANNERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

17           DIFFERENCE BETWEEN A-SCAN AND B-SCAN SOUND WAVES GENERATION

18           GLOBAL OPHTHALMIC ULTRA SOUND IMAGING SYSTEMS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

19           GLOBAL FUNDUS CAMERA MARKET BY GEOGRAPHY  2014-2023 ($ MILLION)

20           COMPARISON BETWEEN DIRECT AND INDIRECT OPHTHALMOSCOPY

21           GLOBAL OPHTHALMOSCOPES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

22           GLOBAL RETINOSCOPE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

23           GLOBAL PACHYMETER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

24           GLOBAL WAVEFRONT ABERROMETERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

25           GLOBAL PERIMETERS/VISUAL FIELD ANALYZER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

26           GLOBAL AUTOREFRACTORS/PHOROPTER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

27           GLOBAL KERATOMETERS 2014-2022 MARKET BY GEOGRAPHY ($ MILLION)

28           GLOBAL SPECULAR MICROSCOPE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

29           GLOBAL CORNEAL TOPOGHAPHERS MARKET BY GEOGRPAHY 2014-2023 ($ MILLION)

30           GLOBAL TONOMETERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

31           GLOBAL SLIT LAMPS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

32           GLOBAL BIOMETERS MARKET BY GEOGRPAHY 2014-2023 ($ MILLION)

33           GLOBAL OTHER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

34           GLOBAL OPHTHALMOLOGY SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

35           GLOBAL CATARACT SURGERY DEVICE MARKET BY GEOGRPAHY  2014-2023 ($ MILLION)

36           GLOBAL REFRACTIVE SURGERY DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

37           GLOBAL VITREORETINAL SURGERY DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

38           PATENT FOR ILLUMINATION SYSTEM IN OPHTHALMIC SURGERY 2015

39           GLOBAL VISION CARE MARKET BY DEVICE 2014-2023 ($ MILLION)

40           GLOBAL VISION CARE DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

41           GLOBAL CONTACT LENS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

42           GLOBAL SPECTACLES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

43           EYE EXAMS AMONG VARIOUS AGE INDIVIDUALS

44           GLOBAL EYE EXAMS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

45           GLOBAL OPHTHALMOLOGY DRUG MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

46           GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2014 - 2022 ($ MILLION)

47           VARIOUS FDA APPROVED DRUGS FOR OPHTHALMOLOGY

48           FDA APPROVED PRESCRIPTION DRUG INFORMATION

49           OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

50           GLOBAL OPHTHAMOLOGY DRUG MARKET BY DELIVERY TYPES 2014-2023 ($ MILLION)

51           TOP SELLING EYE DROPS 2015

52           GLOBAL EYE DROPS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

53           TOP SELLING EYE SUPPLEMENTS BRANDS IN US IN 2014

54           GLOBAL OPHTHALMOLOGY CAPSULES & TABLET MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

55           TOP SELLING EYE OINTMENT IN US 2015

56           GLOBAL EYE OINTMENT MARKET BY GEOGRPAHY 2014-2023 ($ MILLION)

57           GLOBAL EYE GEL MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

58           TOP SELLING EYE SOLUTION IN US 2015

59           GLOBAL EYE SOLUTION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

60           GLOBAL GLAUCOMA DRUG MARKET BY GEOGRAPHY 2014-2022($ MILLION)

61           GLOBAL RETINAL DISORDER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

62           GLOBAL DRY EYE DRUG MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

63           GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET BY GEOGRAPHY 2014-2022($ MILLION)

64           GLOBAL OPHTHALMOLOGY DRUG AND DEVICE MARKET BY THERAPEUTICS 2014-2023 ($ MILLION)

65           SYMPTOMS, TREATMENT, RECOVERY TIME FOR DIABETIC MACULAR EDEMA

66           GLOBAL DIABETIC MACULAR EDEMA MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

67           GLOBAL EYE CANCER MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

68           GLOBAL DIABETIC RETINOPATHY MARKET BY GEOGRAPHY  2014-2023 ($ MILLION)

69           GLOBAL RETINAL VEIN OCCLUSION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

70           GLOBAL DRY EYE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

71           GLOBAL GLAUCOMA THERAPEUTICS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

72           GLOBAL KERATITIS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

73           GLOBAL GEOGRAPHIC ATROPHY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

74           GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2014-2023 ($ MILLION)

75           GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

76           GLOBAL EYE CLINICS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

77           GLOBAL DIAGNOSTIC CENTERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

78           GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

79           GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

80           SUPPORTIVE INITIATIVES WITHIN THE REGION

81           US OPHTHALMIC DRUGS & DEVICE MARKET BY PRODUCT 2014-2023 ($ MILLION)

82           US OPHTHALMIC DRUGS & DEVICES MARKET BY THERAPEUTICS 2014-2022($ MILLION)

83           U.S. HOSPITAL FACT SHEET, 2016

84           US OPHTHALMIC DEVICE MARKET BY TYPE 2014-2022($ MILLION)

85           US VISION CARE DEVICES MARKET BY VISION CARE 2014-2023 ($ MILLION)

86           US OPHTHALMIC DRUGS MARKET BY TYPE OF DISEASE 2014-2023 ($ MILLION)

87           US OPHTHALMIC DRUGS MARKET BY DELIVERY TYPE 2014-2022($ MILLION)

88           INITIATIVES FOR EYE CARE WITHIN THE REGION

89           EUROPE OPHTHALMIC DRUGS & DEVICES MARKET 2014-2023 ($ MILLION)

90           SCENARIO OF HOSPITALS IN RUSSIA 2015

91           ASIA PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET BY REGION 2014-2023 ($ MILLION)

92           INITIATIVES FOR EYE HEALTH IN THE ASIA PACIFIC REGION

93           HUMAN RESOURCES NEED FOR EYE CARE IN INDIA

94           PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA 2014

95           EYE HEALTH STATISTICS IN AUSTRALIA

96           KEY CAUSES OF BLINDNESS IN INDONESIA

FIGURES LIST

1              KEY FINDINGS OF THE REPORT

2              TOP THREE EMERGING COUNTRIES 2015-2022 ($ MILLION)

3              TOP REVENUE GENERATING SEGMENTS 2014-2015 ($ MILLION)

4              BENEFITS SUPPORTING HIGHER CATARACT SURGERIES

5              TREATMENT PROGRESS OVERVIEW

6              MAJOR RESEARCH AND DEVELOPMENT AREAS IN PLASMA TECHNOLOGY IN OPHTHALMOLOGY

7              NUMBER OF CLINICS USING VR SYSTEMS IN VARIOUS GEOGRAPHIES

8              KEY MARKET FACTS

9              GLOBAL OPHTHALMOLOGY DEVICE MARKET SHARE IN 2015

10           GLOBAL OPHTHALMOLOGY DRUGS MARKET SHARE IN 2015

11           PORTERS FIVE FORCE MODEL OF OPHTHALMOLOGY DRUGS & DEVICES MARKET

12           VALUE CHAIN ANALYSIS: OPHTHALMOLOGY DRUG MARKET

13           VALUE CHAIN ANALYSIS OF OPHTHALMOLOGY DEVICES MARKET

14           KEY BUYING CRITERIA

15           KEY BUYING CRITERIA IMPACT

16           ATTRACTIVE INVESTMENT PROPOSITION BY SEGMENT 2015 ($ MILLION)

17           ATTRACTIVE INVESTMENT PROPOSITION BY GEOGRAPHY 2015 ($ MILLION)

18           GLOBAL GERIATRIC POPULATION (65+) 2015 & 2020 (MILLION)

19           PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050

20           WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)

21           PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)

22           GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014

23           HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014

24           HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014

25           HEALTHCARE EXPENDITURE (AS % OF GDP) OF MAJOR APAC COUNTRIES IN 2014

26           GROWTH IN GERIATRIC POPULATION FROM 2010 TO 2015(%)

27           RISK ASSOCIATED WITH THE OCULAR DISEASES

28           BLINDNESS CAUSES WORLDWIDE

29           VISION SCREENING PERFORMED BY EACH GROUP OF PROVIDERS (IN %)

30           GLOBAL CATARACT SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

31           GLOBAL GLAUCOMA SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

32           GLOBAL GLAUCOMA SURGERY DEVICE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

33           GLOBAL REFRACTIVE SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

34           GLOBAL VITREORETINAL SURGERY DEVICE MARKET 2014-2023 ($ MILLION)

35           GLOBAL CONTACT LENS MARKET 2014-2023 ($ MILLION)

36           CONTACT LENS USAGE AMONG VARIOUS AGE GROUPS IN THE U.S. 2015

37           GLOBAL SPECTACLES MARKET 2014-2023 ($ MILLION)

38           EYE EXAMS IN THE U.S. ADULTS 2012-2014 (MILLION)

39           CONSUMPTION OF DRUGS BY TYPES IN 2016

40           GLOBAL EYE DROPS MARKET 2014-2023 ($ MILLION)

41           USAGE OF EYE DROPS AND EYE WASH IN U.S. HOUSEHOLDS 2012-2015 (%)

42           GLOBAL CAPSULES & TABLET MARKET 2014-2023 ($ MILLION)

43           GLOBAL EYE OINTMENT MARKET 2014-2023 ($ MILLION)

44           GLOBAL EYE GEL MARKET 2014-2023 ($ MILLION)

45           GLOBAL EYE SOLUTION MARKET 2014-2023 ($ MILLION)

46           GLOBAL GLAUCOMA DRUG MARKET 2014-2022($ MILLION)

47           DIFFERENT AGE GROUP WITH PROBABILITY OF BEING AFFECTED 2016

48           GLOBAL RETINAL DISORDER DRUGS MARKET 2014-2023 ($ MILLION)

49           GLOBAL DRY EYE DRUG MARKET 2014-2022($ MILLION)

50           GLOBAL ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUGS MARKET 2014-2023 ($ MILLION)

51           SYMPTOMS AND TREATMENT FOR EYE CANCER

52           DIABETIC RETINOPATHY PREVALENCE IN THE U.S. 2011 & 2030 (MILLION)

53           GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

54           GLOBAL CONJUNCTIVITIS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

55           TOTAL OPHTHALMIC CARE HOSPITAL IN US 2014

56           EYE DISEASES CASES ABOVE AGE OF 40 IN AMERICA 2014 (MILLION)

57           TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US IN 2014 (MILLION)

58           CASES ABOVE 40 AGE IN AMERICA 2014 (MILLION)

59           NORTH AMERICA OPHTHALMIC DRUGS & DEVICES MARKET BY REGION 2014-2023 ($ MILLION)

60           UNITED STATES (U.S.) MARKET 2014-2023 ($ MILLION)

61           CAUSES OF VISUAL IMPAIRMENT IN THE U.S. 2014

62           PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014

63           FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA

64           EUROPEAN GERIATRIC POPULATION (65 YEARS AND ABOVE) 2010, 2025 & 2050 (MILLION)

65           PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015

66           ESTIMATED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN UK (MILLION)

67           NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000’S)

68           POPULATION AGED 65 YEARS AND ABOVE IN SPAIN (% OF POPULATION)

69           HEALTHCARE EXPENDITURE IN ASIA PACIFIC COUNTRIES

70           GERIATRIC POPULATION (65 YEARS AND ABOVE) IN JAPAN 2014 & 2060

71           CAUSES OF BLINDNESS IN AUSTRALIA IN 2014

72           AGING POPULATION GROWTH RATE IN LATIN AMERICA 2000-2050

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample


UPCOMING REPORTS

No upcoming reports available under this subcategory.
credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: sales@occamsresearch.com

 

 

Go To Top
viewthroughconversion